Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22852538 | 1.00 | HRH3 (0.34) | HRH3NR1H2SLC6A9ACHECHRM5 | |
| SCHEMBL13257201 | 0.82 | CNR1 (0.39) | NR1H2SLC6A9ACHECHRM5ADRA2C | |
| SCHEMBL12658782 | 0.78 | L3MBTL1 (0.40) | HRH3SLC6A9 | |
| SCHEMBL12299850 | 0.78 | L3MBTL1 (0.40) | HRH3SLC6A9 | |
| SCHEMBL12658780 | 0.78 | L3MBTL1 (0.40) | HRH3SLC6A9 | |
| SCHEMBL13416610 | 0.77 | SLC6A9 (0.38) | HRH3SLC6A9 | |
| SCHEMBL18199163 | 0.77 | SLC6A9 (0.38) | HRH3SLC6A9 | |
| SCHEMBL13416594 | 0.75 | HRH3 (0.39) | HRH3GBA1 | |
| SCHEMBL9891853 | 0.75 | HRH3 (0.39) | HRH3GBA1 | |
| SCHEMBL13015720 | 0.75 | GBA1 (0.45) | NR1H2CNR1CNR2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031954-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | MCL1, ABL1, MALT1 | HRH3 2940/4885NR1H2 3774/4885SLC6A9 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.